Comparative Pharmacology
Head-to-head clinical analysis: LOGILIA versus NORINYL 1 35 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOGILIA versus NORINYL 1 35 28 DAY.
LOGILIA vs NORINYL 1+35 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lorecivivt, the active component of Logilia, is a small interfering RNA (siRNA) that targets the synthesis of transthyretin (TTR) protein. It binds to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type TTR mRNA, leading to its degradation via RNA interference. This reduces TTR protein production and deposition in tissues.
Norethindrone is a progestogen that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing ovulation and altering cervical mucus and endometrial thickness.
100 mg orally once daily.
One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 inert tablets).
None Documented
None Documented
Terminal elimination half-life: 12–15 hours; dose adjustment recommended in renal impairment
Norethindrone: 7-8 hours (terminal half-life); steady state achieved after 5 days. Ethinyl estradiol: biphasic with terminal half-life of 13-27 hours (mean ~17 hours). Clinical context: dosing interval of 24 hours allows stable hormone levels after first cycle.
Approximately 60% renal (as unchanged drug), 40% biliary/fecal
Renal: 50-60% (conjugates and metabolites), Fecal: 30-40% (biliary elimination of norethindrone and ethinyl estradiol conjugates); total clearance ~4-6 mL/min/kg.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive